Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 2/20 | 0.32 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ATM | Q13315 | 1/20 | 0.31 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23137214 | 0.75 | ADORA2A (0.34) | ADORA2AADORA2BKDM4EADORA1 | |
| SCHEMBL16626052 | 0.71 | POLB (0.36) | ADORA2AADORA2B | |
| SCHEMBL24654997 | 0.71 | KMT2A (0.41) | KDM4ECYP1A2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL26817446 | 0.70 | PDE2A (0.42) | KDM4E | |
| SCHEMBL23858559 | 0.70 | KDM4E (0.43) | KDM4ESMN1; SMN2 | |
| SCHEMBL29324067 | 0.69 | KDM4E (0.31) | KDM4ESMN1; SMN2TRPA1 | |
| SCHEMBL25875821 | 0.67 | PDE2A (0.39) | KDM4E | |
| SCHEMBL26200048 | 0.66 | CCR4 (0.32) | KDM4ECYP1A2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL7914279 | 0.64 | CYP1A2 (0.42) | CYP1A2TRPA1 | |
| SCHEMBL30592308 | 0.64 | ADORA2A (0.38) | ADORA2AADORA2BKDM4ECYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240228484-A1 | MONOACYLGLYCEROL LIPASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2024-07-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240228484-A1 | MONOACYLGLYCEROL LIPASE MODULATORS | MGLL, LPL, PNLIP | ADORA2A 1308/4885ADORA2B 909/4885KDM4E 3365/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.